Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enzon PEG-ADA orphan product grant

Executive Summary

The "Severe Combined Immunogencity Disease: Enzyme Therapy" grant provides a total of $169,908 for a three year period to fund the on-going development of the orphan PEG-adenosine deaminase (PEG-ADA) for treatment of children with Severe Combined Immunodeficiency Disease (SCID). FDA designated PEG-ADA an orphan product in 1985.

You may also be interested in...



FDA Authorizes Athletic Collar To Reduce Brain Injuries

The Q-Collar is meant to work by improving blood flow to the brain, and has been shown to reduce signs of trauma from head impacts when playing sports.

Ad Hominis: FDA Authorizes Memic Innovative’s Surgical Robot

The device can conduct laparoscopic hysterectomies, giving surgeons more mobility while leaving less scarring.

BridgeBio Gets First Drug Approval In Ultra-Rare MoCD Type A

Nulibry obtains FDA approval weeks ahead of its action date. Although small patient base offers modest revenue opportunity, approval enables BridgeBio to get commercial operations underway.

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel